ConductScience.org, home
AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
API referenceFor AI assistants

Trial · NCT00528424

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 20

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Reduction in Contracture to 5° or LessAA4500 0.58 mg41.9Percentage of joints
Clinical Improvement After the Last InjectionAA4500 0.58 mg65.0Percentage of joints
Percent Reduction From Baseline Contracture After the Last InjectionAA4500 0.58 mg60.8Standard Deviation 39.00Percentage of change
Change From Baseline Range of Motion After the Last InjectionAA4500 0.58 mg24.0Standard Deviation 20.83Degrees
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 1, Day 112.5Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 1, Day 715.9Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 1, Day 305.9Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 00.0Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 12.2Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 71.3Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 2, Day 301.9Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 00.0Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 11.3Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 70.6Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgInjection 3, Day 300.3Percentage of Joints
Time to Reach Clinical SuccessAA4500 0.58 mgDid not reach Clinical Success58.1Percentage of Joints
Clinical Success After the First InjectionAA4500 0.58 mg34.1Percentage of Joints
Clinical Improvement After the First InjectionAA4500 0.58 mg56.3Percentage of Joints
Percent Reduction From Baseline Contracture After the First InjectionAA4500 0.58 mg53.9Standard Deviation 38.64Percentage of change
Change From Baseline Range of Motion After the First InjectionAA4500 0.58 mg20Standard Deviation 19.46Degrees

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00528424/results

API referenceFor AI assistants